SEC Form 4 · accession 0001209191-17-020688
Sarepta Therapeutics, Inc. · SRPT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Edward M. Kaye M.D.
Officer — President, CEO & CMO · Director
Period of report
Mar 10, 2017
Accepted (ET)
Mar 14, 2017 · 9:47 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000873303
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F1 | $32.63 | Mar 10, 2017 | A | 95,623 | A | — | Mar 10, 2027 | Common Stock | 95,623 | 95,623 | D |
| Incentive Stock Option (right to buy)F1 | $32.63 | Mar 10, 2017 | A | 4,377 | A | — | Mar 10, 2027 | Common Stock | 4,377 | 4,377 | D |
Explanation of responses
- F125% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant.